Cargando…

Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049

Background: Chronic hepatitis B (CHB) is highly prevalent among adults in rural China and better management of those populations is of vital importance for viral hepatitis elimination. Adult immunization has been the subject of much controversy in previous studies. This study estimates the cost-effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xiaolan, Wu, Chensi, Jiang, Lushun, Peng, Chunting, Pan, Liya, Zhang, Xue, Shen, Wei, Chen, Lin, Lou, Zhuoqi, Xu, Kaijin, Li, Lanjuan, Dong, Yin, Ruan, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kerman University of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808295/
https://www.ncbi.nlm.nih.gov/pubmed/34664496
http://dx.doi.org/10.34172/ijhpm.2021.126
_version_ 1784862910085857280
author Xu, Xiaolan
Wu, Chensi
Jiang, Lushun
Peng, Chunting
Pan, Liya
Zhang, Xue
Shen, Wei
Chen, Lin
Lou, Zhuoqi
Xu, Kaijin
Li, Lanjuan
Dong, Yin
Ruan, Bing
author_facet Xu, Xiaolan
Wu, Chensi
Jiang, Lushun
Peng, Chunting
Pan, Liya
Zhang, Xue
Shen, Wei
Chen, Lin
Lou, Zhuoqi
Xu, Kaijin
Li, Lanjuan
Dong, Yin
Ruan, Bing
author_sort Xu, Xiaolan
collection PubMed
description Background: Chronic hepatitis B (CHB) is highly prevalent among adults in rural China and better management of those populations is of vital importance for viral hepatitis elimination. Adult immunization has been the subject of much controversy in previous studies. This study estimates the cost-effectiveness of population-based hepatitis B screening, treatment, and immunization strategy (comprehensive strategy) in rural areas with high prevalence under the national policy of sharp-drop drug prices. Methods: We constructed a Markov model comparing 4 strategies in a 30-year horizon from the healthcare payer perspective: (1) the conventional pattern; (2) screening and treating infected (treatment); (3) screening and immunizing susceptible individuals (immunization); and (4) the comprehensive strategy. Screening intensity ranged from 50% to 100%. Outcomes were measured by costs, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and clinical outcomes. Results: The costs for the conventional pattern, treatment strategy, immunization strategy, and comprehensive strategy were US$ 341, 351, 318, and 323, respectively. In addition, effects were 17.45, 17.57, 17.46, and 17.58 QALYs, respectively. The ICER of the comprehensive strategy was US$ 35/QALY gained at 50% screening intensity and 420 US$/QALY gained at 100%. The net monetary benefit increased with increasing screening intensity and declined after 90%, with the highest value of US$40 693. All new infections and 52.5% mortality could be avoided from 2020 to 2049 if all patients were properly treated and all susceptible individuals were immunized. The results were stable within a wide range of parameters. Conclusion: It was cost-effective to implement the mass hepatitis B screening, treatment, and immunization strategy in areas of rural China with high prevalence, and the strategy gained the most net monetary benefit at a screening intensity of 90%. Although it was impractical to fulfill 100% coverage, efforts should be made to obtain more people screened.
format Online
Article
Text
id pubmed-9808295
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Kerman University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-98082952023-01-10 Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049 Xu, Xiaolan Wu, Chensi Jiang, Lushun Peng, Chunting Pan, Liya Zhang, Xue Shen, Wei Chen, Lin Lou, Zhuoqi Xu, Kaijin Li, Lanjuan Dong, Yin Ruan, Bing Int J Health Policy Manag Original Article Background: Chronic hepatitis B (CHB) is highly prevalent among adults in rural China and better management of those populations is of vital importance for viral hepatitis elimination. Adult immunization has been the subject of much controversy in previous studies. This study estimates the cost-effectiveness of population-based hepatitis B screening, treatment, and immunization strategy (comprehensive strategy) in rural areas with high prevalence under the national policy of sharp-drop drug prices. Methods: We constructed a Markov model comparing 4 strategies in a 30-year horizon from the healthcare payer perspective: (1) the conventional pattern; (2) screening and treating infected (treatment); (3) screening and immunizing susceptible individuals (immunization); and (4) the comprehensive strategy. Screening intensity ranged from 50% to 100%. Outcomes were measured by costs, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and clinical outcomes. Results: The costs for the conventional pattern, treatment strategy, immunization strategy, and comprehensive strategy were US$ 341, 351, 318, and 323, respectively. In addition, effects were 17.45, 17.57, 17.46, and 17.58 QALYs, respectively. The ICER of the comprehensive strategy was US$ 35/QALY gained at 50% screening intensity and 420 US$/QALY gained at 100%. The net monetary benefit increased with increasing screening intensity and declined after 90%, with the highest value of US$40 693. All new infections and 52.5% mortality could be avoided from 2020 to 2049 if all patients were properly treated and all susceptible individuals were immunized. The results were stable within a wide range of parameters. Conclusion: It was cost-effective to implement the mass hepatitis B screening, treatment, and immunization strategy in areas of rural China with high prevalence, and the strategy gained the most net monetary benefit at a screening intensity of 90%. Although it was impractical to fulfill 100% coverage, efforts should be made to obtain more people screened. Kerman University of Medical Sciences 2021-09-07 /pmc/articles/PMC9808295/ /pubmed/34664496 http://dx.doi.org/10.34172/ijhpm.2021.126 Text en © 2022 The Author(s); Published by Kerman University of Medical Sciences https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Xu, Xiaolan
Wu, Chensi
Jiang, Lushun
Peng, Chunting
Pan, Liya
Zhang, Xue
Shen, Wei
Chen, Lin
Lou, Zhuoqi
Xu, Kaijin
Li, Lanjuan
Dong, Yin
Ruan, Bing
Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049
title Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049
title_full Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049
title_fullStr Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049
title_full_unstemmed Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049
title_short Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049
title_sort cost-effectiveness of hepatitis b mass screening and management in high-prevalent rural china: a model study from 2020 to 2049
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808295/
https://www.ncbi.nlm.nih.gov/pubmed/34664496
http://dx.doi.org/10.34172/ijhpm.2021.126
work_keys_str_mv AT xuxiaolan costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT wuchensi costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT jianglushun costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT pengchunting costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT panliya costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT zhangxue costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT shenwei costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT chenlin costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT louzhuoqi costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT xukaijin costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT lilanjuan costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT dongyin costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049
AT ruanbing costeffectivenessofhepatitisbmassscreeningandmanagementinhighprevalentruralchinaamodelstudyfrom2020to2049